Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

NCT04216589 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

NIH

Sponsor class

Conditions

HIV Infections
Non-Alcoholic Fatty Liver Disease

Interventions

DRUG: Semaglutide

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]